Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors

  • M. D. Wissing, J. Mendonca, M. S. Q. Kortenhorst, N. S. Kaelber, M. Gonzalez, E. Kim, H. Hammers, P. J. van Diest, M. A. Carducci, S. K. Kachhap
  • The FASEB Journal, July 2013, Federation of American Societies For Experimental Biology (FASEB)
  • DOI: 10.1096/fj.12-222893

The authors haven't yet claimed this publication.

Read Publication